Sage broadens the spotlight on postpartum depression
Sage is using Zulresso’s launch to raise awareness of postpartum depression
Sage is parlaying the launch of the first drug for postpartum depression into improved awareness and diagnosis, setting up its next therapy to launch into a larger, better prepared market.
On March 19, FDA approved Zulresso brexanolone, a positive-allosteric modulator of the GABA A receptor, on the back of Phase III results showing the compound reduced depressive symptoms within 60 hours, a much speedier time-course than the weeks to months it takes other marketed antidepressants to take effect.
Sage Therapeutics Inc. is using the time until Zulresso’s launch to build awareness for a market that is not only underserved, but under-estimated because routine maternal care stops when the baby arrives.
“A question in our office is, ‘Why does the support end when the baby is born?’ You get all this support before the baby is born but every mom knows the post-baby period is way harder,” Theresa Nguyen, VP of Policy and Programs at Mental